Yu-Hong Li (Yuhong Li)

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 22

Top Topics

Locally Advanced

Ejection Fraction

Top Venues

Therapeutic advances in medical oncology

Cancer medicine

Cancer immunology, immunotherapy : CII

This page only lists publications with an associated author ORCID identifier.

Publications

Zhi-Gang Chen, Xiao-Meng Ji, Yu-Xia Xu, William Pat Fong, Xiao-Yun Liu, Jie-Ying Liang, Qiong Tan, Lei Wen, Yan-Yu Cai, De-Sheng Wang, Yu-Hong Li
Methylated ctDNA predicts early recurrence risk in patients undergoing resection of initially unresectable colorectal cancer liver metastases. Therapeutic advances in medical oncology 16 (2024)
De-Sheng Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLoS medicine 21 (5) (2024)
De-Sheng Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLoS medicine 21 (5) (2024)
Zi-Yao Huang, Lei Wen, Liu-Fang Ye, Yu-Ting Lu, William Pat Fong, Ren-Jing Zhang, Si-Xian Wu, Zhi-Gang Chen, Yan-Yu Cai, Rui-Hua Xu, Yu-Hong Li, Zi-Ming Du, De-Sheng Wang
Clinical and molecular characteristics of RNF43 mutations as promising prognostic biomarkers in colorectal cancer. Therapeutic advances in medical oncology 16 (2024)
Zhi-Gang Chen, Xiao-Meng Ji, Yu-Xia Xu, William Pat Fong, Xiao-Yun Liu, Jie-Ying Liang, Qiong Tan, Lei Wen, Yan-Yu Cai, De-Sheng Wang, Yu-Hong Li
Methylated ctDNA predicts early recurrence risk in patients undergoing resection of initially unresectable colorectal cancer liver metastases. Therapeutic advances in medical oncology 16 (2024)
De-Sheng Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLoS medicine 21 (5) (2024)
Zi-Yao Huang, Lei Wen, Liu-Fang Ye, Yu-Ting Lu, William Pat Fong, Ren-Jing Zhang, Si-Xian Wu, Zhi-Gang Chen, Yan-Yu Cai, Rui-Hua Xu, Yu-Hong Li, Zi-Ming Du, De-Sheng Wang
Clinical and molecular characteristics of RNF43 mutations as promising prognostic biomarkers in colorectal cancer. Therapeutic advances in medical oncology 16 (2024)
Jiaojiao Yang, Liyue Sun, Xiao-Yun Liu, Chan Huang, Junling Peng, Xinxin Zeng, Hailin Zheng, Wenjian Cen, Yu-Xia Xu, Weijie Zhu, Xiao-Yan Wu, Dongyi Ling, Lu-Lu Zhang, Mingbiao Wei, Ye Liu, Deshen Wang, Feng-Hua Wang, Yu-Hong Li, Qin Li, Zi-Ming Du
Targeted demethylation of the CDO1 promoter based on CRISPR system inhibits the malignant potential of breast cancer cells. Clinical and translational medicine 13 (9) (2023)
Feng-Hua Wang, Ming-Ming He, Jian Xiao, Yan-Qiao Zhang, Xiang-Lin Yuan, Wei-Jia Fang, Yan Zhang, Wei Wang, Xiao-Hua Hu, Zhi-Gang Ma, Yi-Chen Yao, Zhi-Xiang Zhuang, Yingying Shi, Jie-Er Ying, Ying Yuan, Qing-Feng Zou, Zeng Qing Guo, Xiang-Yuan Wu, Ying Jin, Zong-Jiong Mai, Zhi-Qiang Wang, Hong Qiu, Ying Guo, Si-Mei Shi, Shuang-Zhen Chen, Hui-Yan Luo, Dong-Sheng Zhang, Feng-Hua Wang, Yu-Hong Li, Rui-Hua Xu
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study). Clinical cancer research : an official journal of the American Association for Cancer Research 28 (19) (2022)
Lei Wen, Zhigang Chen, Xiaomeng Ji, William Pat Fong, Qiong Shao, Chao Ren, Yanyu Cai, Binkui Li, Yunfei Yuan, De-Sheng Wang, Yu-Hong Li
Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation. Journal for immunotherapy of cancer 10 (7) (2022)
Zhiqiang Wang, Mingtao Hu, Yihuai Hu, Qiaoqiao Li, Jiadi Wu, William Pat Fong, Chao Ren, Deshen Wang, Qiong Tan, Hong Yang, Yu-Hong Li
Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial. Esophagus : official journal of the Japan Esophageal Society (2021)
Xiuxing Chen, Ziming Du, Mayan Huang, Deshen Wang, William Pat Fong, Jieying Liang, Lei Fan, Yun Wang, Hui Yang, Zhigang Chen, Mingtao Hu, Ruihua Xu, Yu-Hong Li
Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection. Cancer immunology, immunotherapy : CII (2021)
Jie-Ying Liang, Hao-Cheng Lin, Jingwen Liu, De-Sheng Wang, Yun-Fei Yuan, Bin-Kui Li, Yun Zheng, Xiao-Jun Wu, Gong Chen, Feng-Hua Wang, Zhi-Qiang Wang, Zhi-Zhong Pan, De-Sen Wan, Rui-Hua Xu, Yu-Hong Li
A novel prognostic nomogram for colorectal cancer liver metastasis patients with recurrence after hepatectomy. Cancer medicine 10 (5) (2021)
Jie-Ying Liang, Shao-Yan Xi, Qiong Shao, Yun-Fei Yuan, Bin-Kui Li, Yun Zheng, De-Shen Wang, Xiao-Jun Wu, Pei-Rong Ding, Gong Chen, Li-Ren Li, Feng-Hua Wang, Zhi-Qiang Wang, Zhi-Zhong Pan, Rui-Hua Xu, Yu-Hong Li
Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy. Cancer immunology, immunotherapy : CII 69 (12) (2020)
De-Sheng Wang, Zhi-Qiang Wang, Gong Chen, Jie-Wen Peng, Wei Wang, Yan-Hong Deng, Feng-Hua Wang, Jian-Wei Zhang, Han-Lin Liang, Fen Feng, Chuan-Bo Xie, Chao Ren, Ying Jin, Si-Mei Shi, Wen-Hua Fan, Zhen-Hai Lu, Pei-Rong Ding, Feng Wang, Rui-Hua Xu, Yu-Hong Li
Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer. Cancer medicine 9 (1) (2019)
Yun Wang, Xiao-Qiang Sun, Hao-Cheng Lin, De-Shen Wang, Zhi-Qiang Wang, Qiong Shao, Feng-Hua Wang, Shu-Mei Yan, Jie-Ying Liang, Zhao-Lei Zeng, Huai-Qiang Ju, Rui-Hua Xu, Yu-Hong Li
Correlation between immune signature and high-density lipoprotein cholesterol level in stage II/III colorectal cancer. Cancer medicine 8 (3) (2019)
Miao-Zheng Qiu, Cai-Yun He, Shi-Xun Lu, Wen-Long Guan, Fang Wang, Xiao-Jian Wang, Ying Jin, Feng-Hua Wang, Yu-Hong Li, Jian-Yong Shao, Zhou-Wei Zhou, Jing-Ping Yun, Rui-Hua Xu
Prospective observation: Clinical utility of plasma Epstein-Barr virus DNA load in EBV-associated gastric carcinoma patients. International journal of cancer 146 (1) (2019)
Miao-Zheng Qiu, Si-Mei Shi, Zhan-Hong Chen, Hong-En Yu, Hui Sheng, Ying Jin, De-Shen Wang, Feng-Hua Wang, Yu-Hong Li, Dan Xie, Zhou-Wei Zhou, Da-Jun Yang, Rui-Hua Xu
Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: A SEER-based study. Cancer medicine 7 (8) (2018)
Fei Zhang, Yun Wang, Peng Sun, Zhi-Qiang Wang, De-Shen Wang, Dong-Sheng Zhang, Feng-Hua Wang, Jian-Hua Fu, Rui-Hua Xu, Yu-Hong Li
Fibrinogen promotes malignant biological tumor behavior involving epithelial-mesenchymal transition via the p-AKT/p-mTOR pathway in esophageal squamous cell carcinoma. Journal of cancer research and clinical oncology 143 (12) (2017)
Feng-Hua Wang, Yun Wang, Guo-Ping Sun, Jian-Hua Chen, Ying-Cheng Lin, Wei Liu, Rong-Sheng Zheng, Jia Chen, He-Long Zhang, Hai-Tao Lan, Jun Qi, Yang-Qing Liu, Yan-Ming Deng, Heng Zhao, Jian-Ping Xiong, Qing Xu, Wen-Qi Jiang, Yu-Hong Li
Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial. Cancer 123 (20) (2017)
Yun Wang, Hao-Cheng Lin, Ma-Yan Huang, Qiong Shao, Zhi-Qiang Wang, Feng-Hua Wang, Yun-Fei Yuan, Bin-Kui Li, De-Shen Wang, Pei-Rong Ding, Gong Chen, Xiao-Jun Wu, Zhen-Hai Lu, Li-Ren Li, Zhi-Zhong Pan, Peng Sun, Shu-Mei Yan, De-Sen Wan, Rui-Hua Xu, Yu-Hong Li
The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases. Cancer immunology, immunotherapy : CII 67 (3) (2017)
Feng-Hua Wang, Yun Wang, Zhen-Dong Chen, Jian-Hua Chen, Feng-Zhan Qin, Wen-Qi Jiang, Yu-Hong Li
A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma. Medical oncology (Northwood, London, England) 33 (11) (2016)